Across TCGA pan-cancer cohorts, RBM33 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RBM33 data layer compared with 29 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM33 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM33 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

HNSC, PDAC, and COAD are the cancer types where RBM33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.140	1.000	.017	14	view →
PDAC	DFS	Tertile	All	0.472	0.202	.017	7	view →
COAD	DFS	Median	III,IV	1.000	0.899	.046	6	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.554	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RBM33 tumor-vs-normal RNA expression · all RBM33 data types